en

Clinical Trials Procedures

Slovak republic has adopted Commission directives 2001/20/EC and 2005/28/EC into Act No. 362/2011 Col. There are some differences in the procedures between Slovak Acts and these directives.

 

Fees should be paid before submission of application: 

Clinical trial of medicinal product for human use: 331,50 € 

The bank account (payment from foreign countries):

 

BENEFICIARY´s ACCOUNT No. (IBAN):

SK3481800000007000133673

BANK:         

Všeobecná úverová banka, a. s.

Mlynské Nivy 1

829 90 Bratislava

Slovak Republic

 

SWIFT (BIC): SUBASKBX 

BENEFICIARY:

Štátny ústav pre kontrolu liečiv

Kvetná 11

825 08 Bratislava

Slovak Republic

 

REMITANCE INFORMATION

(EudraCT Number without hyphens and dashes) 

The bank account (domestic payment): 

BENEFICIARY´s ACCOUNT No.

7000133673/8180 

BANK:          Štátna pokladnica

Radlinského 32

810 05 Bratislava

 

VARIABLE SYMBOL:

EudraCT Number without hyphens and dashes. 

There are no exemptions for academic research.

 

Request for a clinical trial authorization should contain at least:

 1.     Covering Letter

Especially identification of the applicant and sponsor and list of submitted documents should be included in covering letter. As administrative procedure should be in official language covering letter should be in Slovak language or bilingual.

1.1. Extract from business register (commercial person) or copy of license (physical person).

1.2. If the applicant is not the sponsor, a power of attorney enabling the applicant to act on behalf of the sponsor.

 2.      Application form

Printed and signed application form accessed via internet at the address https://eudract.ema.europa.eu/ with data relevant for Slovak republic. All addresses should be correct and in Slovak language.

2.1. Receipt of confirmation of EUDRACT number

2.1. Copy of XML file of Application form on CD.

3.    Investigator’s Brochure

4.    Protocol

4.1    Including all actual amendments

4.2   List of relevant community pharmacies in the case when trial site does not have a hospital pharmacy or trial site do not have suitable conditions of IMP storing.

4.3   Statement that the trial will be conducted in compliance with the protocol, GCP and the applicable regulatory requirements.

5.     Subject information leaflet (in Slovak language)

6.     Informed consent form (in Slovak language)

7.     Investigational Medicinal Product Dossier (IMPD)

Full IMPD with declaration of GLP

Or Simplified IMPD

Or Summary of product characteristics

8.   A copy of authorisation (licence) of health care provider(s) acting as trial site(s)

9.   Applicable authorisations to cover trials or products with special characteristics e. g. GMOs (Ministry of the Environment of the Slovak republic),. Radiopharmaceuticals (Public Health Authority of the Slovak Republic),

10. Copy of ethics committee opinion 

Print page
eu-flag.png sk-flag.png